Alfred von Krempelhuber

Author

Bavarian Nordic (Germany)ORCID

Also Known As

A von Krempelhuber, A. von Krempelhuber, Alfred von Krempelhuber

Publications

816

Citations

H-Index

Concepts

All Affiliations

Bavarian Nordic (Germany)GlaxoSmithKline (Germany)University of Kentucky GlaxoSmithKline (Belgium)University of Alabama at Birmingham

About

Alfred von Krempelhuber is an author at Bavarian Nordic (Germany) specializing in vaccination, medicine, and vaccinology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	316
2	Immunology	2	2	262
3	Immunotherapy	2	2	194
4	Allergy	1	1	54
5	Immunodominance	1	1	140

Alfred von Krempelhuber

Publications

797

Citations

H-Index

Page 1

	Year	Citations
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial Edgar T. Overton, Jack T. Stapleton, Ian Frank, Open Forum Infectious Diseases VaccinationVaccine SafetyVaccinologyVaccine DevelopmentHealthy Subjects	2015	140
Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects Richard N. Greenberg, Edgar T. Overton, David W. Haas, The Journal of Infectious Diseases	2012	131
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE® Alfred von Krempelhuber, Jens Vollmar, Rolf Pokorny, Vaccine VaccinologyVaccine SafetyVaccinationVaccine DevelopmentThird Generation	2009	122
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis Richard N. Greenberg, Yadira Hurley, Dinh V. Dinh, PLoS ONE	2015	113
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects Richard N. Greenberg, Christine M. Hay, Jack T. Stapleton, PLoS ONE	2016	80
Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis Frank von Sonnenburg, Pamela Perona, Ulf Darsow, Vaccine VaccinologyVaccine SafetyVaccinationAllergyAtopic Dermatitis	2014	54
Cardiac Safety of Modified Vaccinia Ankara for Vaccination against Smallpox in a Young, Healthy Study Population Eva-Maria Zitzmann-Roth, Frank von Sonnenburg, Stephan de la Motte, PLoS ONE	2015	50
Assessment of the potential public health impact of Herpes Zoster vaccination in Germany Desmond Curran, Desirée Van Oorschot, Lijoy Varghese, Human Vaccines & Immunotherapeutics	2017	45
Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study Ruprecht Schmidt‐Ott, Ulf Schutter, Jörg Simon, Journal of Infection	2018	42
Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old Desirée Van Oorschot, Anastassia Anastassopoulou, B Poulsen Nautrup, Human Vaccines & Immunotherapeutics	2018	20

Page 1